We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Vývoj léčby chronické myeloidní leukemie v posledních 25 letech.
- Authors
Faber, E.; Indrák, K.
- Abstract
Introduction of tyrosine kinase inhibitors into the treatment of chronic myeloid leukaemia (CML) over the past 25 years has resulted in a revolutionary change and has had a crucial impact on global treatment strategies in oncology. CML has been transformed from a deadly malignancy into a chronic disorder with patients today dying more frequently from other illnesses and patient overall survival equalling that of the general population. As treatment efficacy rises, prevention and management of side effects is of growing importance. The logical next step is an attempt to stop treatment in optimally responding patients with the aim of maintaining treatment-free remission. On the other hand, a small fraction of high-risk patients can still profit from bone marrow transplantation and these patients may profit prospectively from the introduction of new classes of inhibitors acting outside the ABL kinase domain. Cure of CML with targeted conservative treatment has become the long-term aim. This review discusses the developments in CML treatment over the past 25 years with emphasis on the Czech contribution.
- Publication
Transfusiology & Haematology Today / Transfuze a Hematologie Dnes, 2019, Vol 25, Issue 1, p118
- ISSN
1213-5763
- Publication type
Article